Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
AgeneBio logo — company profile

AgeneBio

Founded 2008 United States Baltimore, United States 4 employees Grant Biotechnology, Health Care +1

General Information

Company Name AgeneBio
Founded Year 2008
Location United States Baltimore, United States
Employees 4
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with AgeneBio. To contact AgeneBio, visit agenebio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AgeneBio compare?

A PDF of AgeneBio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AgeneBio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About AgeneBio

AgeneBio, Inc. is an emerging pharmaceutical company founded in 2008 that is focused on developing innovative therapeutics to address the unmet needs of patients battling amnestic mild cognitive impairment (aMCI) and other neurodegenerative and psychiatric diseases. The company's lead candidate, AGB101, is Phase 3-ready and aims to be the first therapeutic targeting hippocampal overactivity, potentially delaying the progression to Alzheimer's dementia. This approach is based on research conducted at Johns Hopkins University and other leading research centers, demonstrating that controlling hippocampal overactivity can preserve and restore cognitive function. AgeneBio also has a promising GABA-A alpha5 small molecule program with potential therapeutic applications for various untreated conditions including aMCI, autism, and schizophrenia. The company received a grant investment on 13 September 2019. For more information, visit www.agenebio.com or follow them on Twitter at @AgeneBio.

Funding Rounds & Investors (11)

View All
Funding Stage Amount Investors Lead Investors Date
Grant Undisclosed -
13 Sep 2019
Grant Undisclosed -
11 Oct 2018
Debt Financing Undisclosed -
06 Feb 2015
Venture Series Unknown Undisclosed -
01 Jan 2015
Venture Series Unknown Undisclosed -
17 Oct 2014
Venture Series Unknown Undisclosed -
18 Nov 2013
Venture Series Unknown Undisclosed -
04 Jun 2013
Debt Financing Undisclosed -
25 Sep 2012
Debt Financing Undisclosed -
22 Dec 2011
Debt Financing Undisclosed -
12 Apr 2010

View All 11 Funding Rounds

FAQ About AgeneBio

AgeneBio, Inc., is an emerging pharmaceutical company dedicated to developing innovative therapeutics that prevent neurodegeneration and preserve and restore cognitive function for unserved patients battling amnestic mild cognitive impairment (aMCI), the symptomatic pre-dementia stage of Alzheimer’s...
AgeneBio was founded in 2008.
AgeneBio is headquartered in Baltimore, United States.
AgeneBio operates in Biotechnology, Health Care and Pharmaceutical.
AgeneBio has approximately 4 employees.
AgeneBio has completed 11 funding rounds. The latest funding stage is Grant.

We're actively collecting intelligence on AgeneBio.

Source: BounceWatch company record for AgeneBio, https://bouncewatch.com/company/agenebio, updated 7 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout